Skip to main content

Table 7 Comparison between the evaluation of response based on RECIST 1.1 and the evaluation of response based on the combined response approach

From: Predicting response to neo-adjuvant chemotherapy and assessment of residual disease in breast cancer using contrast-enhanced spectral mammography: a combined qualitative and quantitative approach

  Sensitivity Specificity PPV NPV
RECIST 1.1 evaluation 76.67% (46/60)
95% CI 63.9–86.6
66.67% (14/21)
95% CI 43.03–85.4
86.79% (46/53)
95% CI 77.9–92.4
50% (14/28)
95% CI 36.6–63.4
Combined evaluation 95.00% (57/60)
95% CI 86.08–98.9
61.90% (13/21)
95% CI 38.4–81.9
87.69% (57/65)
95% CI 80.4–92.5
81.25% (13/16}
95% CI 57.7–93.2